Synthesis and discovery of the first potent proteolysis targeting chimaera (PROTAC) degrader of AIMP2-DX2 as a lung cancer drug

References

• Kim S, You S, Hwang D. Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping. Nat Rev Cancer. 2011;11(10):708–718.
   PubMed Web of Science ®Google Scholar
• Kwon NH, Fox PL, Kim S. Aminoacyl- tRNA synthetases as therapeutic targets. Nat Rev Drug Discov. 2019;18(8):629–650. − 
   PubMed Web of Science ®Google Scholar
• Han JM, Lee MJ, Park SG, Lee SH, Razin E, Choi E-C, Kim S. Hierarchical network between the components of the multi-tRNA synthetase complex: implications for complex formation. J Biol Chem. 2006;281(50):38663–38667.
   PubMed Web of Science ®Google Scholar
• Sivaraman A, Kim DG, Bhattarai D, Kim M, Lee HY, Lim S, Kong J, Goo J-I, Shim S, Lee S, et al. Synthesis and structure–activity relationships of arylsulfonamides as AIMP2- DX2 inhibitors for the development of a novel anticancer therapy. J Med Chem. 2020;63(10):5139–5158.
   PubMed Web of Science ®Google Scholar
• Choi JW, Kim DG, Lee AE, Kim HR, Lee JY, Kwon NH, Shin YK, Hwang SK, Chang SH, Cho MH, et al. Cancer-associated splicing variant of tumor suppressor AIMP2/p38: pathological implication in tumorigenesis. PLoS Genet. 2011;7(3):e1001351.
   PubMed Web of Science ®Google Scholar
• Jung JY, Kim EY, Kim A, Chang J, Kwon NH, Moon Y, Kang EJ, Sung JS, Shim H, Kim S, et al. Ratio of autoantibodies of tumor suppressor AIMP2 and its oncogenic variant is associated with clinical outcome in lung cancer. J Cancer. 2017;8(8):1347–1354.
   PubMed Web of Science ®Google Scholar
• Choi JW, Lee JW, Kim JK, Jeon HK, Choi JJ, Kim DG, Kim BG, Nam DH, Kim HJ, Yun SH, et al. Splicing variant of AIMP2 as an effective target against chemoresistant ovarian cancer. J Mol Cell Biol. 2012;4(3):164–173.
   PubMed Web of Science ®Google Scholar
• Kim DG, Choi Y, Lee Y, et al. AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis. Nat Commun. 2022;13:2572.
   PubMed Web of Science ®Google Scholar
• Lim S, Cho HY, Kim DG, Roh Y, Son SY, Mushtaq AU, Kim M, Bhattarai D, Sivaraman A, Lee Y, et al. Targeting the interaction of AIMP2-DX2 with HSP70 suppresses cancer development. Nat Chem Biol. 2020;16(1):31–41.
   PubMed Web of Science ®Google Scholar
• Lee HS, Kim DG, Oh YS, Kwon NH, Lee JY, Kim D, Park SH, Song JH, Lee S, Han JM, et al. Chemical suppression of an oncogenic splicing variant of AIMP2 induced tumour regression. Biochem J. 2013;454(3):411–416.
   PubMed Web of Science ®Google Scholar
• Oh AY, Jung YS, Kim J, Lee JH, Cho JH, Chun HY, Park S, Park H, Lim S, Ha NC, et al. Inhibiting DX2-p14/ARF Interaction exerts antitumor effects in lung cancer and delays tumor progression. Cancer Res. 2016;76(16):4791–4804.
   PubMed Web of Science ®Google Scholar
• Lee S, Kim DG, Kim K, Kim T, Lim S, Kong H, Kim S, Suh Y-G. 2-Aminophenylpyrimidines as novel inhibitors of aminoacyl-tRNA synthetase interacting multifunctional protein 2 (AIMP2)-DX2 for lung cancer treatment. J Med Chem. 2020;63(8):3908–3914.
   PubMed Web of Science ®Google Scholar
• Lee BRa, Gyu Kim D, Mi Kim Y, Kim S, Choi I. Discovery of benzodioxane analogues as lead candidates of AIMP2-DX2 inhibitors. Bioorg Med Chem Lett. 2022;73:128889.
   PubMed Web of Science ®Google Scholar
• Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov. 2017;16(2):101–114.
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang Y, Wang J, Xing D. VHL-based PROTACs as potential therapeutic agents: recent progress and perspectives. Eur J Med Chem. 2022;227:113906.
   PubMed Web of Science ®Google Scholar
• Wurz RP, Dellamaggiore K, Dou H, Javier N, Lo M-C, McCarter JD, Mohl D, Sastri C, Lipford JR, Cee VJ. A “bro” for the rapid synthesis of bispecific molecules for inducing protein degradation. J Med Chem. 2018;61(2):453–461.
   PubMed Web of Science ®Google Scholar
• Zhou B, Hu J, Xu F, Chen Z, Bai L, Fernandez-Salas E, Lin M, Liu L, Yang CY, Zhao Y, et al. Discovery of small-molecule degrader of bromodomain and extraterminal (BET) protein with picomolar cellular potencies and capable of achieving tumor regression. J Med Chem. 2018;61(2):462–481.
   PubMed Web of Science ®Google Scholar
• Lohbeck J, Miller AK. Practical synthesis of a phthalimide-based cereblon ligand to enable PROTAC development. Bioorg Med Chem Lett. 2016;26(21):5260–5262.
   PubMed Web of Science ®Google Scholar
• Qiu X, Sun N, Kong Y, Li Y, Yang X, Jiang B. Chemoselective synthesis of lenalidomide-based PROTAC library using alkylation reaction. Org Lett. 2019;21(10):3838–3841.
   PubMed Web of Science ®Google Scholar
• Li W, Gao C, Zhao L, Yuan Z, Chen Y, Jiang Y. Phthalimide conjugations for the degradation of oncogenic PI3K. Eur J Med Chem. 2018;151:237–247.
   PubMed Web of Science ®Google Scholar
• Rimsa V, Eadsforth TC, Hunter WN. Two high-resolution structure of the human E3 ubiquitin ligase Siah1. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2013;69(Pt 12):1339–1343.
   PubMedGoogle Scholar
• Tian W, Chen C, Lei X, Zhao J, Liang J. CASTp3.0: computed atlas of surface topography of proteins. Nucleic Acids Res. 2018; 46(W1):W363–W367.
   PubMed Web of Science ®Google Scholar
• Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complex. J Med Chem. 2006;49(21):6177–6196.
   PubMed Web of Science ®Google Scholar